{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:34:04Z","timestamp":1794090844130,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.10.085","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T22:00:13Z","timestamp":1415743213000},"page":"174-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety and immunogenicity of an MF59\u00ae-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age"],"prefix":"10.1016","volume":"33","author":[{"given":"Markus","family":"Knuf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans. C.","family":"R\u00fcmke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Abarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pedotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Kieninger-Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Della Cioppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.10.085_bib0005","unstructured":"World Health Organization. World now at the start of 2009 influenza pandemic, available at \u3008http:\/\/www.who.int\/mediacentre\/news\/statements\/2009\/h1n1_pandemic_phase6_20090611\/en\/\u3009 (last accessed November 13, 2014)"},{"key":"10.1016\/j.vaccine.2014.10.085_bib0010","unstructured":"World Health Organization. Global alert and response (GAR)-pandemic (H1N1) 2009-update 112: weekly update [Last updated 2010 Aug 06], available at \u3008http:\/\/www.who.int\/entity\/csr\/don\/2010_08_06\/en\/index.html\u3009 (last accessed November 13, 2014)"},{"issue":"9","key":"10.1016\/j.vaccine.2014.10.085_bib0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2014.10.085_bib0020","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMoa0905498","article-title":"Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States","volume":"361","author":"Cauchemez","year":"2009","journal-title":"N Engl J Med"},{"issue":"5934","key":"10.1016\/j.vaccine.2014.10.085_bib0025","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.1176062","article-title":"Pandemic potential of a strain of influenza A (H1N1): early findings","volume":"324","author":"Fraser","year":"2009","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.vaccine.2014.10.085_bib0030","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa0906695","article-title":"Hospitalized patients with 2009 H1N1 influenza in the United States: April\u2013June 2009","volume":"361","author":"Jain","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2014.10.085_bib0035","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"issue":"5948","key":"10.1016\/j.vaccine.2014.10.085_bib0040","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1126\/science.1175570","article-title":"Optimizing influenza vaccine distribution","volume":"325","author":"Medlock","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.085_bib0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2014.10.085_bib0050","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59((R))-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.085_bib0055","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1542\/peds.2009-2628","article-title":"Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence","volume":"126","author":"Vesikari","year":"2010","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.085_bib0060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.085_bib0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"26","key":"10.1016\/j.vaccine.2014.10.085_bib0070","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2014.10.085_bib0075","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"Tsai","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.10.085_bib0080","series-title":"European public assessment report for Focetria","author":"European Medicines Agency","year":"2010"},{"issue":"23","key":"10.1016\/j.vaccine.2014.10.085_bib0085","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2012.03.017","article-title":"A randomized clinical trial to identify the optimal antigen and MF59((R)) adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.10.085_bib0090","unstructured":"World Health Organization. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A; Published May 27, 2009, available at \u3008http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/candidates_X-179a\/en\/\u3009 (last accessed November 13, 2014)"},{"issue":"8","key":"10.1016\/j.vaccine.2014.10.085_bib0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","article-title":"Confronting the avian influenza threat: vaccine development for a potential pandemic","volume":"4","author":"Stephenson","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"9272","key":"10.1016\/j.vaccine.2014.10.085_bib0100","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2014.10.085_bib0105","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titres as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"16","key":"10.1016\/j.vaccine.2014.10.085_bib0110","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.vaccine.2008.11.036","article-title":"Guidelines for collection: analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies","volume":"27","author":"Bonhoeffer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.10.085_bib0115","series-title":"Note for guidance on harmonization of requirements for influenza vaccines","author":"Committee for the Proprietary Medical Products","year":"1997"},{"issue":"9523","key":"10.1016\/j.vaccine.2014.10.085_bib0120","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"issue":"9587","key":"10.1016\/j.vaccine.2014.10.085_bib0125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2014.10.085_bib0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.085_bib0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/hv.7.1.13411","article-title":"Assessment of the safety: tolerability and kinetics of the immune response to A\/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age","volume":"7","author":"Arguedas","year":"2011","journal-title":"Hum Vaccines"},{"issue":"25","key":"10.1016\/j.vaccine.2014.10.085_bib0140","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.vaccine.2014.10.085_bib0145","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2012.03.053","article-title":"Assessment of the immunogenicity and safety of varying doses of an MF59(R)-adjuvanted cell culture-derived A\/H1N1 pandemic influenza vaccine in Japanese paediatric: adult and elderly subjects","volume":"30","author":"Fukase","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.085_bib0150","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A\/H1N1 influenza vaccine in children 3 to <9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"26","key":"10.1016\/j.vaccine.2014.10.085_bib0155","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.vaccine.2011.04.011","article-title":"Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents","volume":"29","author":"Garcia-Sicilia","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2014.10.085_bib0160","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/655830","article-title":"AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age","volume":"51","author":"Roman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"45","key":"10.1016\/j.vaccine.2014.10.085_bib0165","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1016\/j.vaccine.2010.08.075","article-title":"Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2014.10.085_bib0170","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","article-title":"MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination","volume":"27","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2014.10.085_bib0175","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12325-010-0043-4","article-title":"Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A\/H1N1v vaccine in Japanese children","volume":"27","author":"Yasuda","year":"2010","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.085_bib0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1750-2659.2011.00229.x","article-title":"Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis","volume":"5","author":"Yin","year":"2011","journal-title":"Influenza Other Respir Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T21:21:37Z","timestamp":1538083297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14015047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X14015047"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an MF59\u00ae-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}